Brainsway (NASDAQ:BWAY) Upgraded by Wall Street Zen to “Buy” Rating

Brainsway (NASDAQ:BWAY) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday.

A number of other equities analysts have also issued reports on BWAY. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price (up from $16.00) on shares of Brainsway in a research report on Thursday. Northland Securities boosted their price target on Brainsway from $15.00 to $19.00 and gave the company an “outperform” rating in a report on Thursday.

Brainsway Stock Up 1.2%

Shares of BWAY opened at $12.98 on Friday. The business’s 50 day moving average is $12.08 and its two-hundred day moving average is $10.53. Brainsway has a 52-week low of $7.06 and a 52-week high of $13.65. The firm has a market cap of $245.32 million, a price-to-earnings ratio of 49.92 and a beta of 1.42.

Brainsway (NASDAQ:BWAY) last announced its earnings results on Wednesday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. Brainsway had a return on equity of 8.97% and a net margin of 11.60%. The company had revenue of $12.63 million for the quarter, compared to analyst estimates of $12.34 million. On average, equities analysts expect that Brainsway will post 0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Brainsway

A number of institutional investors have recently made changes to their positions in BWAY. Lazard Asset Management LLC bought a new stake in shares of Brainsway in the 4th quarter valued at approximately $44,000. Raymond James Financial Inc. bought a new stake in shares of Brainsway in the 2nd quarter valued at approximately $85,000. GAMMA Investing LLC increased its holdings in shares of Brainsway by 720.7% in the 1st quarter. GAMMA Investing LLC now owns 9,356 shares of the company’s stock valued at $89,000 after acquiring an additional 8,216 shares during the last quarter. Palumbo Wealth Management LLC bought a new stake in shares of Brainsway in the 1st quarter valued at approximately $111,000. Finally, Trexquant Investment LP bought a new stake in shares of Brainsway in the 1st quarter valued at approximately $129,000. 30.11% of the stock is currently owned by institutional investors.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.